Section Arrow
ALT.NASDAQ
- Altimmune
Quotes are at least 15-min delayed:2025/09/04 02:29 EDT
Regular Hours
Last
 3.68
-0.07 (-1.87%)
Day High 
3.84 
Prev. Close
3.75 
1-M High
3.9072 
Volume 
1.60M 
Bid
3.69
Ask
3.7
Day Low
3.66 
Open
3.73 
1-M Low
3.335 
Market Cap 
330.96M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.61 
20-SMA 3.6 
50-SMA 4.1 
52-W High 11.16 
52-W Low 2.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.18/-1.38
Enterprise Value
332.37M
Balance Sheet
Book Value Per Share
1.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
20.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
STTKShattuck Labs1.28+0.27+26.73%-- 
Quotes are at least 15-min delayed:2025/09/04 02:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.